CYTOX-LIMITED
13.3.2019 07:02:09 CET | Business Wire | Press release
Cytox , a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s (AD) and other neurological diseases, has announced that in collaboration with Cardiff University it will be making a poster and short oral presentation at the multidisciplinary 14th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2019 ), March 26-31 in Lisbon, Portugal. The presentation will share results on the high accuracy of Cytox’s pioneering SNPfitRTM , an analytical software platform that contains multiple PRS algorithms, in predicting clinical Alzheimer’s disease in both carriers and non-carriers of ApoE4 risk allele, with validation and optimization in independent, well-characterized cohorts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI). In addition, the prediction accuracy in carriers was significantly increased compared with the accuracy achieved using ApoE (E4/E2), age and gender.
Poster 249, ‘The Utility of Polygenic Risk Scores to Identify Individuals for Clinical Trials in Alzheimer’s Disease’, will be displayed all day on March 27th , as part of the ‘Imaging, Biomarkers, Diagnostics: Other’ session in the Exhibition Hall at the Lisbon Congress Centre and an oral presentation will be given by Eftychia Bellou, Cardiff University, Cardiff, United Kingdom, in the Short Oral Session 02 – Presentations of Selected Posters on March 28th , 09:15 - 11:15, Auditorium V.
Richard Pither, CEO of Cytox, commented “The importance of Cytox’s PRS approach is gaining increasing attention for estimating individual genetic risk profile and disease risk prediction in Alzheimer’s – essential in the selection of individuals for clinical trials and cohort studies. Recent results from an international collaborative study have validated this, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals. The results we are presenting at AD/PD further show that SNPfitR provides a valuable platform for determining genetic risk in dementia in both carriers and non-carriers of ApoE4, with the advantage of requiring only blood or saliva-extracted DNA, thus reducing reliance on expensive PET imaging procedures.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005741/en/
Contact:
Cytox Limited Richard Pither, CEO +44(0)1865338018 richard.pither@cytoxgroup.com www.cytoxgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom